Calcium channel blockers enhance extrarenal potassium disposal in the rat.

@article{Sugarman1986CalciumCB,
  title={Calcium channel blockers enhance extrarenal potassium disposal in the rat.},
  author={A. Sugarman and T. Kahn},
  journal={The American journal of physiology},
  year={1986},
  volume={250 4 Pt 2},
  pages={
          F695-701
        }
}
The effect of calcium channel blockers on the extrarenal disposition of an acute potassium load was examined in acutely nephrectomized rats infused with KCl (0.75 meq X kg-1 X h-1 for 60 min) alone or in combination with either verapamil or nifedipine. The increment in plasma potassium concentration during the potassium infusion (delta PK) with either verapamil or nifedipine was less than control (P less than 0.05 and 0.01, respectively). Studies were repeated in acutely adrenalectomized rats… Expand
Effects of Calcium Antagonists on Adrenaline-Induced Hypokalaemia
TLDR
The results suggest that enhancement of the adrenaline-induced intracellular transfer of potassium from the extracellular space is relatively specific to dihydropyridine calcium antagonists. Expand
The role of aldosterone in potassium tolerance: studies in anephric humans.
TLDR
Plasma aldosterone levels were low, positively correlated to the serum potassium and similar in all three periods without evidence of feedback inhibition by DOCA or stimulated by spironolactone. Expand
Effects of calcium channel blockers on potassium homeostasis.
TLDR
Clinically, there are no reports of either hyperkalemia or hypokalemia with the routine therapeutic use of these agents given alone, and review of the data indicates that current evidence implicating this class of drugs in the pathogenesis of disordered potassium regulation remains equivocal. Expand
Dissociation of vascular and adrenal responsiveness to angiotensin II following calcium channel blockade.
TLDR
A tissue specificity for the effects of different classes of calcium channel blockers is suggested by the in vivo observations showing that angiotensin II-stimulated aldosterone secretion was markedly blunted by isradipine and minimally by diltiazem. Expand
Extrarenal potassium tolerance in chronic renal failure: implications for the treatment of acute hyperkalemia.
  • M. Salem, R. Rosa, D. Batlle
  • Medicine
  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 1991
TLDR
The available data suggest that with the development of ESRD and the uremic syndrome there is impaired extrarenal potassium metabolism that is related to a defect in the Na,K-adenosine triphosphatase (ATPase) and a regimen for the treatment of life-threatening hyperkalemia is outlined. Expand
Calcium antagonists and potassium balance.
TLDR
The studies have shown that verapamil and nifedipine enhance the extrarenal disposal of an acute intravenous potassium load administered to acutely nephrectomized rats, and postulated that the impaired calcium entry into cells mediated by the intervention of insulin, aldosterone, or β 2 -catecholamines. Expand
Antihypertensive and metabolic effects of verapamil: role of Na-K-ATPase and electrolytes homeostasis in male and female rats.
TLDR
The results showed that the changes in electrolyte levels are more pronounced in female than in male rats, which suggests that verapamil lower blood pressure by correcting a pathophysiological derangements of electrolytes present in hypertension. Expand
Impaired potassium-induced insulin secretion in chronic renal failure.
TLDR
K(+)-induced insulin secretion by islets isolated from CRF rats was significantly lower than that from normal,CRF-PTX, CRF-V and normal-V rats, and the calcium signal and the delta/basal [Ca2+]i ratio in response to 20 mM KCl observed in islets fromCRF rats wereificantly lower than in the other four groups of animals. Expand
Renal Effects of Antihypertensive Drugs
TLDR
There is emerging evidence from human studies supporting a distinctive beneficial effect of these agents on renal function in patients with hypertension, mild chronic renal insufficiency and diabetes mellitus. Expand
Diltiazem enhances potassium disposal in subjects with end-stage renal disease.
  • R. Solomon, A. Dubey
  • Medicine
  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 1992
TLDR
In ESRD, diltiazem significantly reduced the rate of increase in plasma potassium compared with placebo and resulted in a significantly lower net increase in potassium over the entire 28-hour period, which did not affect plasma potassium in normal subjects. Expand
...
1
2
...